Follow-up appointments will be scheduled to monitor your progress and make any necessary adjustments to your treatment plan
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus in adults
(It held up in both Black and White women, too.) Now 30% less sounds dramatic, but the absolute number is calmer: about seven fewer breast cancers per thousand women
Another study reported that the bitter taste of berberine causes the activation of bitter taste receptors (TAS2Rs), which further activates the downstream signalling pathway, leading to enhanced GLP-1 secretion 4
In clinical trials like the landmark FLOW study, semaglutide demonstrated strong renoprotective (kidney-protecting) benefits, significantly slowing down the progression of chronic kidney disease (CKD) and reducing kidney function decline in patients with type 2 diabetes
the trial design largely excluded these agents, which is an important consideration when interpreting the hypoglycaemia data